EGFR-mutated non-small-cell lung cancer
EGFR-mutated lung cancer is driven by a single faulty growth receptor and is treated first with a pill rather than chemotherapy. Osimertinib keeps the disease under control for about a year and a half on average, adding chemotherapy or the antibody amivantamab extends that further, and three years of osimertinib after surgery roughly halves the risk of death in early-stage disease.
Overview
EGFR mutations were discovered in 2004 when three Boston groups worked out why a minority of lung cancers, mostly in never-smoking women and East Asian patients, melted away on gefitinib. The IPASS trial (2009) then showed that in mutation carriers gefitinib beat chemotherapy and in non-carriers it was worse, which made EGFR testing mandatory before first-line treatment and established the model of a driver mutation matched to a pill. Exon 19 deletions and L858R are the classical sensitising mutations; exon 20 insertions are resistant to the classical inhibitors; and uncommon mutations (G719X, L861Q, S768I) respond best to afatinib or osimertinib.
Osimertinib, designed against the T790M resistance mutation, beat gefitinib and erlotinib first line in FLAURA (2018): median progression-free survival 18.9 versus 10.2 months and overall survival 38.6 versus 31.8 months, with far less brain progression. Two trials then built on it: FLAURA2 (2023) added platinum-pemetrexed to osimertinib (progression-free survival 25.5 versus 16.7 months, hazard ratio 0.62, with the 2025 survival analysis also in favour), and MARIPOSA (2024) combined the EGFR-MET bispecific antibody amivantamab with lazertinib (23.7 versus 16.6 months, hazard ratio 0.70, and longer overall survival), at the cost of rash, nail changes and venous thrombosis. For exon 20 insertions, PAPILLON (2023) showed amivantamab plus chemotherapy beat chemotherapy (11.4 versus 6.7 months, hazard ratio 0.40) and sunvozertinib was approved in 2025 after platinum chemotherapy. After osimertinib the escape routes are MET amplification (osimertinib plus savolitinib), C797S, small-cell transformation and, most often, no identifiable mechanism, where amivantamab plus chemotherapy (MARIPOSA-2) and the TROP2 antibody-drug conjugate datopotamab deruxtecan are the options.
In early disease ADAURA (2020) showed that three years of adjuvant osimertinib after resection cut recurrence by 83 percent in stage II to IIIA (hazard ratio 0.17) and improved five-year overall survival from 78 to 88 percent, and LAURA (2024) showed that osimertinib after chemoradiation for unresectable stage III disease extended progression-free survival from 5.6 to 39.1 months. Checkpoint inhibitors work poorly in EGFR-mutated disease and are held back until targeted options are exhausted. Open questions are how to choose between the three first-line strategies, whether circulating tumour DNA clearance can guide escalation, and how to prevent rather than treat resistance.
State of the art
- Amivantamab plus chemotherapy (PAPILLON) and sunvozertinib for exon 20 insertions, a group that had no effective targeted drug until 2021.
- Adjuvant osimertinib (ADAURA) and post-chemoradiation osimertinib (LAURA) extend targeted therapy into curative-intent disease.
- Datopotamab deruxtecan approved in 2025 for disease that has progressed on an EGFR inhibitor and chemotherapy.
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Three first-line strategies with osimertinib as the anchor: alone, with chemotherapy (FLAURA2) or replaced by amivantamab plus lazertinib (MARIPOSA), with overall survival gains for the combinations.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowFainting or palpitations
Fainting, near-fainting, or an irregular or racing heartbeat; several kinase inhibitors prolong the QT interval and the labels require ECG and electrolyte monitoring.
- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Emergency services nowSkin reaction
Blisters, peeling, or sores in the mouth or eyes with a rash. Enfortumab vedotin carries a boxed warning for Stevens-Johnson syndrome and toxic epidermal necrolysis, mostly in the first cycle.
- Call the 24-hour line nowInterstitial lung disease or pneumonitis
Any new or worsening cough, breathlessness or fever. The label says to interrupt treatment for any suspected ILD and to permanently discontinue for grade 2 or higher.
- Check before combiningFood and drink: Amivantamab
No food effect (intravenous or subcutaneous antibody).
- Check before combiningHeart rhythm (QT): Osimertinib
Known QT prolongation. Avoid other QT-prolonging drugs where possible; check ECG and correct potassium and magnesium before and during treatment.
See all on the product pages:AmivantamabCarboplatinDatopotamab deruxtecanLazertinibOsimertinibPemetrexedPlatinum + etoposide (EP / CE)SavolitinibSunvozertinib·Printable cards in the navigator
Anatomy and lymph node drainage
- Central airways (squamous, small-cell)
- Periphery (adenocarcinoma)
- Apex (Pancoast)
- Pleura (mesothelioma)
- Thymus (anterior mediastinum)
- Nodes: hilar (N1)
- Nodes: mediastinal (N2)
- Nodes: supraclavicular (N3)
Central tumours arise in the large airways, peripheral ones in the alveoli; both drain to hilar then mediastinal nodes, and the pleural lining is a separate cancer site.
- Central airways (squamous, small-cell)EGFR-mutated disease transformed to small-cell lung cancer
- Periphery (adenocarcinoma)EGFR exon 19 deletion adenocarcinoma (about 45 percent) · EGFR L858R adenocarcinoma (about 40 percent) · EGFR exon 20 insertion (about 10 percent; amivantamab, sunvozertinib) · Uncommon EGFR mutations (G719X, L861Q, S768I; afatinib or osimertinib) · T790M or C797S after EGFR inhibitor therapy · EGFR-mutated disease transformed to small-cell lung cancer
- Apex (Pancoast)
- Pleura (mesothelioma)
- Thymus (anterior mediastinum)EGFR exon 19 deletion adenocarcinoma (about 45 percent) · EGFR L858R adenocarcinoma (about 40 percent)
- hilar (N1)
- mediastinal (N2)
- supraclavicular (N3)
Same organ: Non-small-cell lung cancer, Lung cancer (all types), Small-cell lung cancer, Mesothelioma, Pleural mesothelioma, Thymoma and thymic carcinoma, Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours), Inflammatory myofibroblastic tumour (IMT), ALK-positive non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, RET fusion-positive non-small-cell lung cancer, BRAF V600E-mutant non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, NTRK fusion-positive non-small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation, Resectable stage I to III non-small-cell lung cancer, Unresectable stage III non-small-cell lung cancer, Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Lung neuroendocrine tumours (typical and atypical carcinoid)
About 15 percent of lung adenocarcinomas in Europe and North America and 40 to 50 percent in East Asia carry an activating EGFR mutation; it is the commonest driver in never-smokers and in women. Exon 19 deletions and L858R make up about 85 percent of cases, exon 20 insertions about 10 percent.
- Liquid biopsy (ctDNA)Standard of care
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Osimertinib alone (FLAURA), osimertinib plus platinum-pemetrexed (FLAURA2) for patients with high burden or brain metastases who can take chemotherapy, or amivantamab plus lazertinib (MARIPOSA) with prophylaxis against rash and clots.
Amivantamab plus carboplatin-pemetrexed first line (PAPILLON); sunvozertinib after platinum chemotherapy.
Biopsy or plasma test for the mechanism: osimertinib plus savolitinib for MET amplification; otherwise amivantamab plus platinum chemotherapy (MARIPOSA-2), platinum-pemetrexed, or datopotamab deruxtecan after chemotherapy; platinum-etoposide for small-cell transformation.
Surgery, adjuvant platinum chemotherapy where indicated, then three years of osimertinib (ADAURA).
Concurrent platinum chemoradiation followed by osimertinib until progression (LAURA) rather than durvalumab.
Osimertinib has high brain penetration and is preferred; stereotactic radiosurgery for symptomatic or large lesions; high-dose osimertinib for leptomeningeal disease.
Subtypes & biomarkers
top- EGFR exon 19 deletion adenocarcinoma (about 45 percent)
- EGFR L858R adenocarcinoma (about 40 percent)
- EGFR exon 20 insertion (about 10 percent; amivantamab, sunvozertinib)
- Uncommon EGFR mutations (G719X, L861Q, S768I; afatinib or osimertinib)
- T790M or C797S after EGFR inhibitor therapy
- EGFR-mutated disease transformed to small-cell lung cancer
- EGFR mutation by tissue or plasma sequencing before first-line therapy (exon 19 deletion, L858R, exon 20 insertion, uncommon)
- T790M and C797S at progression
- MET amplification at progression (fluorescence in situ hybridisation or sequencing)
- Circulating tumour DNA clearance during treatment (under study)
- Repeat biopsy at progression for small-cell transformation
- PD-L1 (of limited use; checkpoint inhibitors work poorly)
How often this target appears
- 2004EGFR mutations found to explain gefitinib responses in Boston (Lynch, Paez, Pao)
- 2009IPASS: gefitinib beats chemotherapy in EGFR-mutant patients, worse in others; testing becomes mandatory
- 2015Osimertinib approved for T790M resistance after first-generation inhibitors
- 2018FLAURA: first-line osimertinib beats gefitinib and erlotinib
- 2020ADAURA: three years of adjuvant osimertinib cuts recurrence by 83 percent
- 2021Amivantamab approved for exon 20 insertions after chemotherapy (CHRYSALIS)
- 2023FLAURA2 and PAPILLON: chemotherapy added to osimertinib; amivantamab plus chemotherapy for exon 20
- 2024MARIPOSA: amivantamab plus lazertinib approved first line; LAURA: osimertinib after chemoradiation in stage III
- 2025Sunvozertinib approved for exon 20 insertions; datopotamab deruxtecan approved after EGFR inhibitor and chemotherapy
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 18 changes by month →- 2026-09-17This recordEGFR-mutated non-small-cell lung cancerFacts on this page last checked
When this page itself was last checked or edited.
- 2025Trial resultHERTHENA-Lung02HERTHENA-Lung02 reported
PFS HR 0.
- 2025MilestoneSunvozertinibSunvozertinib approved for exon 20 insertions; datopotamab deruxtecan approved after EGFR inhibitor and chemotherapy
A milestone in how this cancer is treated.
- 2024Trial resultLAURALAURA reported
PFS HR 0.
- 2024MilestoneMARIPOSAMARIPOSA: amivantamab plus lazertinib approved first line; LAURA: osimertinib after chemoradiation in stage III
A milestone in how this cancer is treated.
- 2023Trial resultFLAURA2FLAURA2 reported
PFS HR 0.
What is in development for EGFR-mutated non-small-cell lung cancer, drawn from the whole corpus: 21 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Drugs in phase 3 · 3
Drugs in phase 2 · 2
Technologies being tested · 1
Trials under way · 5
- Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib · phase 2 · AstraZeneca
- REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) · phase 3 · Taiho Oncology
- A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure · phase 3 · Janssen Research & Development, LLC
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions · phase 3 · Janssen Research & Development, LLC
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) · phase 1/2 · Dizal Pharmaceuticals
Trials reported · 8
- HERTHENA-Lung02 · phase 3 · 2025 · mixed
- ADAURA · phase 3 · 2020 · positive
- FLAURA · phase 3 · 2018 · positive
- FLAURA2 · phase 3 · 2023 · positive
- Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial) · phase 3 · 2020 · positive
- LAURA · phase 3 · 2024 · positive
- MARIPOSA · phase 3 · 2023 · positive
- TROPION-Lung05 · phase 2 · 2023 · positive
Combinations being explored · 1
Ideas not yet in a trial · 1
Open problems and what is being done
No head-to-head trial compares the three first-line strategies, and the added toxicity of the combinations falls on every patient for a benefit concentrated in some.
and how the field plans to fix it →What is being done about thisSide effects and quality of lifeAvailable now- Antibody-drug conjugate (ADC)Approved
- IMRT / IGRT (modern external beam)Standard of care
In trialsNothing recorded yet.
Ideas and roadmapsNothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Most resistance to osimertinib has no identifiable mechanism and no targeted option.
and how the field plans to fix it →What is being done about thisResistance to treatmentAvailable now- AmivantamabApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- MRD / molecular residual disease testingEstablished
- OsimertinibApproved
- Small-molecule kinase inhibitorsStandard of care
Ideas and roadmapsBackground: Drug resistance (primary and acquired), EGFR C797S, Histologic transformation, MET amplification (bypass resistance). Also on OnCo: Resistance atlas · Lines of therapy.
Whether adjuvant osimertinib cures more patients or delays recurrence beyond the three years of treatment is still being followed.
and how the field plans to fix it →What is being done about thisRecurrence and residual diseaseAvailable now- Liquid biopsy (ctDNA)Standard of care
- MRD / molecular residual disease testingEstablished
In trials- ADAURAPositive
Ideas and roadmapsNothing recorded yet.
Background: Neoadjuvant / adjuvant / perioperative. Also on OnCo: Treatment journeys · Survivorship planner.
Checkpoint inhibitors add little and increase pneumonitis when combined with EGFR inhibitors.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
Houston · cancer center | United States | 0 | 6,724 | 95,007 | #2 | ||
| South Korea | none recorded | 0 | 1,312 | 17,172 | #3 | ||
Rochester, MN · hospital | United States | 0 | 4,511 | 44,748 | #5 | ||
Villejuif · cancer center | France | none recorded | 0 | 1,855 | 31,182 | #6 | |
| South Korea | none recorded | 0 | 1,607 | 24,676 | #8 | ||
Baltimore · cancer center | United States | 0 | 2,955 | 41,449 | #10 | ||
Berlin · university | Germany | none recorded | 0 | 1,563 | 17,749 | #12 | |
Tokyo · government | Japan | none recorded | 0 | 1,599 | 21,937 | none recorded | #13 |
| United States | 0 | 3,582 | 54,857 | #16 | |||
Cleveland · hospital | United States | 0 | 2,264 | 29,412 | #20 | ||
Seoul · hospital | South Korea | none recorded | 0 | 464 | 3,248 | #22 | |
Stanford · university | United States | 0 | 3,000 | 50,162 | #30 | ||
San Francisco · cancer center | United States | 0 | 2,800 | 46,704 | #33 | ||
Stockholm · university | Sweden | none recorded | 0 | 987 | 12,440 | #39 | |
Amsterdam · cancer center | Netherlands | none recorded | 0 | 1,451 | 25,873 | #45 |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with EGFR-mutated non-small-cell lung cancer but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about EGFR-mutated non-small-cell lung cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example EGFR mutation by tissue or plasma sequencing before first-line therapy, T790M and C797S at progression, MET amplification at progression, Circulating tumour DNA clearance during treatment, Repeat biopsy at progression for small-cell transformation), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include EGFR exon 19 deletion adenocarcinoma, EGFR L858R adenocarcinoma, EGFR exon 20 insertion.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Advanced, first line (exon 19 deletion or L858R)
- For my situation (advanced, first line (exon 19 deletion or l858r)), which of the standard options do you recommend and why?Why: Guideline options include: Osimertinib alone (FLAURA), osimertinib plus platinum-pemetrexed (FLAURA2) for patients with high burden or brain metastases who can take chemotherapy, or amivantamab plus lazertinib (MARIPOSA) with prophylaxis against rash and clots.
- Am I a candidate for Osimertinib, Amivantamab, Lazertinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of FLAURA and FLAURA2 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Advanced, exon 20 insertion
- For my situation (advanced, exon 20 insertion), which of the standard options do you recommend and why?Why: Guideline options include: Amivantamab plus carboplatin-pemetrexed first line (PAPILLON); sunvozertinib after platinum chemotherapy.
- Am I a candidate for Amivantamab, Sunvozertinib, Carboplatin or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions and Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Advanced, after osimertinib
- For my situation (advanced, after osimertinib), which of the standard options do you recommend and why?Why: Guideline options include: Biopsy or plasma test for the mechanism: osimertinib plus savolitinib for MET amplification; otherwise amivantamab plus platinum chemotherapy (MARIPOSA-2), platinum-pemetrexed, or datopotamab deruxtecan after chemotherapy; platinum-etoposide for small-cell transformation.
- Am I a candidate for Amivantamab, Savolitinib, Datopotamab deruxtecan or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure and Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Resected stage IB to IIIA
- For my situation (resected stage ib to iiia), which of the standard options do you recommend and why?Why: Guideline options include: Surgery, adjuvant platinum chemotherapy where indicated, then three years of osimertinib (ADAURA).
- Am I a candidate for Osimertinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of ADAURA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Unresectable stage III
- For my situation (unresectable stage iii), which of the standard options do you recommend and why?Why: Guideline options include: Concurrent platinum chemoradiation followed by osimertinib until progression (LAURA) rather than durvalumab.
- Am I a candidate for Osimertinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of LAURA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Brain and leptomeningeal metastases
- For my situation (brain and leptomeningeal metastases), which of the standard options do you recommend and why?Why: Guideline options include: Osimertinib has high brain penetration and is preferred; stereotactic radiosurgery for symptomatic or large lesions; high-dose osimertinib for leptomeningeal disease.
- Am I a candidate for Osimertinib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Savolitinib, Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib, Patritumab deruxtecan, HERTHENA-Lung02?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No head-to-head trial compares the three first-line strategies, and the added toxicity of the combinations falls on every patient for a benefit concentrated in some”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Most resistance to osimertinib has no identifiable mechanism and no targeted option”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with EGFR-mutated non-small-cell lung cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
12targets
5drugs
19companies
17pathways
4terms
15trials
13pairings
1ideas
1people
11key papers
3Patients newly diagnosed with EGFR-mutated advanced lung cancer now have a first-line option that improves survival over osimertinib, particularly if they have high-risk features. The trade-off is intravenous (now subcutaneous) infusions and considerably more skin, nail and clotting toxicity, so osimertinib alone remains reasonable for those who prioritise convenience and tolerability. Both this regimen and osimertinib plus chemotherapy (FLAURA2) are approved; there is no direct comparison.
Every resected non-squamous lung cancer should be tested for EGFR mutations, because patients who carry one live longer if they take osimertinib for three years after surgery. The trial does not tell us whether adjuvant chemotherapy can be omitted, nor what happens on relapse after osimertinib, and the three-year duration was chosen empirically.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
Latest papers
topQuery for this cancer: (TITLE:"EGFR-mutated non-small-cell lung cancer" OR ABSTRACT:"EGFR-mutated non-small-cell lung cancer" OR TITLE:"EGFR-mutant lung cancer" OR ABSTRACT:"EGFR-mutant lung cancer" OR TITLE:"EGFR-positive NSCLC" OR ABSTRACT:"EGFR-positive NSCLC" OR TITLE:"EGFR exon 19 deletion lung cancer" OR ABSTRACT:"EGFR exon 19 deletion lung cancer" OR TITLE:"EGFR L858R lung cancer" OR ABSTRACT:"EGFR L858R lung cancer" OR TITLE:"EGFR exon 20 insertion lung cancer" OR ABSTRACT:"EGFR exon 20 insertion lung cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about EGFR-mutated non-small-cell lung cancer, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerMET exon 14 and MET-amplified non-small-cell lung cancer
Shares Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib, A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure, MET amplification (bypass resistance), Savolitinib and the tags subtype-page, lung.
- CancerALK-positive non-small-cell lung cancer
Shares Tony S. K. Mok, Yi-Long Wu, ctDNA-guided dose holidays for lung cancer targeted therapy, Brain metastases (intracranial disease) and the tags subtype-page, lung.
- CancerHER2-mutant non-small-cell lung cancer
Shares Pasi A. Jänne, Afatinib, Brain metastases (intracranial disease), Driver mutation and the tags subtype-page, lung.
- CancerUnresectable stage III non-small-cell lung cancer
Shares David Planchard, LAURA, Suresh S. Ramalingam, Yi-Long Wu and the tags subtype-page, lung.
- CancerROS1-positive non-small-cell lung cancer
Shares Byoung Chul Cho, Brain metastases (intracranial disease), Tyrosine kinase inhibitor (TKI), Oncogene addiction and the tags subtype-page, lung.
- CancerResectable stage I to III non-small-cell lung cancer
Shares EGFR exon 19 deletion & L858R, Lobectomy, Yi-Long Wu, Roy S. Herbst and the tags subtype-page, lung.
- CancerRET fusion-positive non-small-cell lung cancer
Shares Brain metastases (intracranial disease), Tyrosine kinase inhibitor (TKI), Oncogene addiction, Non-small cell lung cancer (KEGG map) and the tags subtype-page, lung.
- CancerKRAS G12C-mutant non-small-cell lung cancer
Shares Tony S. K. Mok, Pasi A. Jänne, Brain metastases (intracranial disease), Driver mutation and the tags subtype-page, lung.